Results 161 to 170 of about 541,048 (356)

Long‐term human papillomavirus genotype‐specific risk of cervical high‐grade intraepithelial lesion and cancer—By age group and triage cytology

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Human papillomavirus (HPV) testing has revolutionized cervical cancer screening. Nonetheless, its optimal use for distinguishing between high‐ and low‐risk infections to leverage screening benefits remains to be established. Here, long‐term HPV genotype‐specific risk of precancerous cervical intraepithelial neoplasia grade 2 or higher was ...
Maija Vahteristo   +6 more
wiley   +1 more source

Obstetrics and Gynecology [PDF]

open access: yes, 2005
中村 隆文   +7 more
core   +1 more source

Adult T‐cell leukemia/lymphoma in French Guiana (1990–2019): Epidemiology, clinical features, and HTLV‐1 genetic diversity in the two main ethnic populations

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Adult T‐cell leukemia/lymphoma (ATL) is a rare and aggressive malignancy caused by human T‐cell leukemia virus type 1 (HTLV‐1). The authors comprehensively analyzed the epidemiological and clinical features of ATL over a 30‐year period in French Guiana, a region with high HTLV‐1 endemicity and a multiethnic population.
Jill‐Léa Ramassamy   +16 more
wiley   +1 more source

Under which realistic circumstances is hrHPV self‐sampling increasing cervical screening effectiveness in a partly vaccinated population? A modelling study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Offering the option of self‐sampling in cervical cancer screening programs could increase participation. However, it could also prompt participants to switch from clinician‐collecting sampling, which has demonstrated higher testing sensitivity and lower loss to follow‐up.
Sylvia Kaljouw   +4 more
wiley   +1 more source

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

open access: yesInternational Journal of Cancer, EarlyView.
What's New? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy